ALK-Abello A/S (AKBLF)
37.92
0.00 (0.00%)
USD |
OTCM |
Aug 25, 16:00
ALK-Abello Enterprise Value : 8.212B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 8.212B |
| August 24, 2026 | 8.212B |
| August 21, 2026 | 8.212B |
| August 20, 2026 | 8.212B |
| August 19, 2026 | 8.212B |
| August 18, 2026 | 8.212B |
| August 17, 2026 | 8.212B |
| August 14, 2026 | 8.212B |
| August 13, 2026 | 8.212B |
| August 12, 2026 | 8.212B |
| August 11, 2026 | 8.212B |
| August 10, 2026 | 8.212B |
| August 07, 2026 | 8.212B |
| August 06, 2026 | 8.212B |
| August 05, 2026 | 8.212B |
| August 04, 2026 | 8.212B |
| August 03, 2026 | 8.212B |
| July 31, 2026 | 8.212B |
| July 30, 2026 | 8.212B |
| July 29, 2026 | 8.212B |
| July 28, 2026 | 8.212B |
| July 27, 2026 | 8.212B |
| July 24, 2026 | 8.212B |
| July 23, 2026 | 8.212B |
| July 22, 2026 | 8.212B |
| Date | Value |
|---|---|
| July 21, 2026 | 8.212B |
| July 20, 2026 | 8.212B |
| July 17, 2026 | 8.212B |
| July 16, 2026 | 8.212B |
| July 15, 2026 | 8.818B |
| July 14, 2026 | 8.818B |
| July 13, 2026 | 8.818B |
| July 10, 2026 | 8.818B |
| July 09, 2026 | 8.818B |
| July 08, 2026 | 8.818B |
| July 07, 2026 | 8.818B |
| July 06, 2026 | 8.818B |
| July 02, 2026 | 8.818B |
| July 01, 2026 | 8.818B |
| June 30, 2026 | 8.818B |
| June 29, 2026 | 8.832B |
| June 26, 2026 | 8.832B |
| June 25, 2026 | 8.832B |
| June 24, 2026 | 8.832B |
| June 23, 2026 | 8.832B |
| June 22, 2026 | 8.832B |
| June 18, 2026 | 8.832B |
| June 17, 2026 | 8.832B |
| June 16, 2026 | 8.832B |
| June 15, 2026 | 8.442B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novo Nordisk A/S | 177.36B |
| H. Lundbeck A/S | 7.692B |
| AstraZeneca PLC | 552.52B |
| ANI Pharmaceuticals, Inc. | 1.972B |
| Corcept Therapeutics, Inc. | 13.04B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 52.74M |
| Revenue (Quarterly) | 279.27M |
| Total Expenses (Quarterly) | 226.53M |
| EPS Diluted (Quarterly) | 0.2377 |
| Gross Profit Margin (Quarterly) | 66.57% |
| Profit Margin (Quarterly) | 18.89% |
| Earnings Yield | 2.52% |
| Operating Earnings Yield | 3.39% |
| Normalized Earnings Yield | 2.520 |